MedTrace Logo

Tucatinib Together With Pembrolizumab and Trastuzumab

NCT04789096 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-06-06

No results posted yet for this study

Summary

Women or men with HER2-positive, metastatic breast cancer, who have progressed on previous treatment, will receive tucatinib in combination with pembrolizumab and trastuzumab (PD-L1 positive).

Conditions

Interventions

DRUG

Tucatinib

Oral tablet

DRUG

Pembrolizumab

Intravenous

DRUG

Trastuzumab

Intravenous

DRUG

Capecitabine

Oral tablet

Sponsors & Collaborators

  • Breast Cancer Trials, Australia and New Zealand

    lead OTHER

Principal Investigators

  • Heath Badger · Breast Cancer Trials, Australia and New Zealand

  • Sherene Loi, Prof · Peter MacCallum Cancer Centre, Australia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-07
Primary Completion
2025-06-04
Completion
2025-06-04
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04789096 on ClinicalTrials.gov